SEARCH

SEARCH BY CITATION

References

  • 1
    Jadoul M, Cornu C, van Ypersele de Strihou C. Incidence and risk factors for hepatitis C seroconversion in hemodialysis: a prospective study. The UCL Collaborative Group. Kidney Int 1993; 44: 13221326.
  • 2
    Huang CS, Ho MS, Yang CS, Lee CL, Tan CA. Hepatitis C markers in hemodialysis patients. J Clin Microbiol 1993; 31: 17641769.
  • 3
    Pereira BJ, Levey AS. Hepatitis C virus infection in dialysis and renal transplantation. Kidney Int 1997; 51: 981999.
  • 4
    Fabrizi F, Martin P, Dixit V, Bunnapradist S, Dulai G. Meta-analysis: effect of hepatitis C virus infection on mortality in dialysis. Aliment Pharmacol Ther 2004; 20: 12711277.
  • 5
    Legendre C, Garrigue V, Le Bihan C, Mamzer-Bruneel MF, Chaix ML, Landais P, et al. Harmful long-term impact of hepatitis C virus infection in kidney transplant recipients. Transplantation 1998; 65: 667670.
  • 6
    Gentil MA, Rocha JL, Rodriguez-Algarra G, Pereira P, Lopez R, Bernal G, et al. Impaired kidney transplant survival in patients with antibodies to hepatitis C virus. Nephrol Dial Transplant 1999; 14: 24552460.
  • 7
    Bruchfeld A, Wilczek H, Elinder CG. Hepatitis C infection, time in renal-replacement therapy, and outcome after kidney transplantation. Transplantation 2004; 78: 745750.
  • 8
    Manga Sahin G, Sahin S, Kantarci G, Ergin H. Impact of hepatitis C virus infection on patient and graft survival in kidney transplantation. Transplant Proc 2006; 38: 499501.
  • 9
    Fabrizi F, Dulai G, Dixit V, Bunnapradist S, Martin P. Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients. Aliment Pharmacol Ther 2003; 18: 10711081.
  • 10
    Rocha CM, Perez RM, Ferreira AP, Carvalho-Filho RJ, Pace FH, Silva IS, et al. Efficacy and tolerance of interferon-alpha in the treatment of chronic hepatitis C in end-stage renal disease patients on hemodialysis. Liver Int 2006; 26: 305310.
  • 11
    Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001; 344: 495500.
  • 12
    Sabovic M, Salobir B, Preloznik Zupan I, Bratina P, Bojec V, Buturovic Ponikvar J. The influence of the haemodialysis procedure on platelets, coagulation and fibrinolysis. Pathophysiol Haemost Thromb 2005; 34: 274278.
  • 13
    Lebrec D, Goldfarb G, Degott C, Rueff B, Benhamou JP. Transvenous liver biopsy: an experience based on 1000 hepatic tissue samplings with this procedure. Gastroenterology 1982; 83: 338340.
  • 14
    Lebrec D. Various approaches to obtaining liver tissue: choosing the biopsy technique. J Hepatol 1996; 25( Suppl 1): 2024.
  • 15
    Cotler SJ, Diaz G, Gundlapalli S, Jakate S, Chawla A, Mital D, et al. Characteristics of hepatitis C in renal transplant candidates. J Clin Gastroenterol 2002; 35: 191195.
  • 16
    Ahmad A, Hasan F, Abdeen S, Sheikh M, Kodaj J, Nampoory MR, et al. Transjugular liver biopsy in patients with end-stage renal disease. J Vasc Interv Radiol 2004; 15: 257260.
  • 17
    Ozdogan M, Ozgur O, Boyacioglu S, Coskun M, Kart H, Ozdal S, et al. Percutaneous liver biopsy complications in patients with chronic renal failure. Nephron 1996; 74: 442443.
  • 18
    Terjung B, Lemnitzer I, Dumoulin FL, Effenberger W, Brackmann HH, Sauerbruch T, et al. Bleeding complications after percutaneous liver biopsy: an analysis of risk factors. Digestion 2003; 67: 138145.
  • 19
    Varaut A, Fontaine H, Serpaggi J, Verkarre V, Vallet-Pichard A, Nalpas B, et al. Diagnostic accuracy of the fibrotest in hemodialysis and renal transplant patients with chronic hepatitis C virus. Transplantation 2005; 80: 15501555.
  • 20
    Furusyo N, Hayashi J, Kanamoto-Tanaka Y, Ariyama I, Etoh Y, Shigematsu M, et al. Liver damage in hemodialysis patients with hepatitis C virus viremia: a prospective 10-year study. Dig Dis Sci 2000; 45: 22212228.
  • 21
    Boyacioglu S, Gur G, Yilmaz U, Korkmaz M, Demirhan B, Bilezikci B, et al. Investigation of possible clinical and laboratory predictors of liver fibrosis in hemodialysis patients infected with hepatitis C virus. Transplant Proc 2004; 36: 5052.
  • 22
    Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. HEPATOLOGY 2003; 38: 518526.
  • 23
    Mathurin P, Mouquet C, Poynard T, Sylla C, Benalia H, Fretz C, et al. Impact of hepatitis B and C virus on kidney transplantation outcome. HEPATOLOGY 1999; 29: 257263.
  • 24
    Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002; 97: 26142618.
    Direct Link:
  • 25
    Siddique I, El-Naga HA, Madda JP, Memon A, Hasan F. Sampling variability on percutaneous liver biopsy in patients with chronic hepatitis C virus infection. Scand J Gastroenterol 2003; 38: 427432.
  • 26
    Scheuer PJ. Liver biopsy size matters in chronic hepatitis: bigger is better. HEPATOLOGY 2003; 38: 13561358.
  • 27
    Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. HEPATOLOGY 2003; 38: 14491457.
  • 28
    Ustundag Y, Bilezikci B, Boyacioglu S, Kayatas M, Odemir N. The utility of AST/ALT ratio as a non-invasive demonstration of the degree of liver fibrosis in chronic HCV patients on long-term haemodialysis. Nephrol Dial Transplant 2000; 15: 17161717.
  • 29
    Fabrizi F, Lunghi G, Finazzi S, Colucci P, Pagano A, Ponticelli C, et al. Decreased serum aminotransferase activity in patients with chronic renal failure: impact on the detection of viral hepatitis. Am J Kidney Dis 2001; 38: 10091015.
  • 30
    Aster RH. Pooling of platelets in the spleen: role in the pathogenesis of “hypersplenic” thrombocytopenia. J Clin Invest 1966; 45: 645657.
  • 31
    Kamimoto Y, Horiuchi S, Tanase S, Morino Y. Plasma clearance of intravenously injected aspartate aminotransferase isozymes: evidence for preferential uptake by sinusoidal liver cells. HEPATOLOGY 1985; 5: 367375.
  • 32
    Kawasaki T, Takeshita A, Souda K, Kobayashi Y, Kikuyama M, Suzuki F, et al. Serum thrombopoietin levels in patients with chronic hepatitis and liver cirrhosis. Am J Gastroenterol 1999; 94: 19181922.
    Direct Link:
  • 33
    Boccardo P, Remuzzi G, Galbusera M. Platelet dysfunction in renal failure. Semin Thromb Hemost 2004; 30: 579589.
  • 34
    Hu KQ, Lee SM, Hu SX, Xia VW, Hillebrand DJ, Kyulo NL. Clinical presentation of chronic hepatitis C in patients with end-stage renal disease and on hemodialysis versus those with normal renal function. Am J Gastroenterol 2005; 100: 20102018.
    Direct Link:
  • 35
    Luzar B, Ferlan-Marolt V, Brinovec V, Lesnicar G, Klopcic U, Poljak M. Does end-stage kidney failure influence hepatitis C progression in hemodialysis patients? Hepatogastroenterology 2003; 50: 157160.
  • 36
    Rampino T, Arbustini E, Gregorini M, Guallini P, Libetta C, Maggio M, et al. Hemodialysis prevents liver disease caused by hepatitis C virus: role of hepatocyte growth factor. Kidney Int 1999; 56: 462463.
  • 37
    Sterling RK, Sanyal AJ, Luketic VA, Stravitz RT, King AL, Post AB, et al. Chronic hepatitis C infection in patients with end-stage renal disease: characterization of liver history and viral load in patients awaiting renal transplantation. Am J Gastroenterol 1999; 94: 35763582.
    Direct Link:
  • 38
    Martin P, Carter D, Fabrizi F, Dixit V, Conrad AJ, Artinian L, et al. Histopathological features of hepatitis C in renal transplant candidates. Transplantation 2000; 69: 14791484.
  • 39
    Westin J, Lagging LM, Wejstal R, Norkrans G, Dhillon AP. Interobserver study of liver histopathology using the Ishak score in patients with chronic hepatitis C virus infection. Liver 1999; 19: 169170.